<DOC>
	<DOCNO>NCT01177384</DOCNO>
	<brief_summary>This study evaluate whether addition sitagliptin reduces hemoglobin A1C ( A1C ) addition placebo participant type 2 diabetes mellitus ( T2DM ) steady dose acarbose . The primary hypothesis addition sitagliptin 100 mg daily ( q.d . ) reduce A1C addition placebo participant T2DM inadequate glycemic control acarbose monotherapy .</brief_summary>
	<brief_title>Clinical Trial Evaluate Safety Efficacy Addition Sitagliptin Participants With Type 2 Diabetes Mellitus Receiving Acarbose Monotherapy ( MK-0431-130 )</brief_title>
	<detailed_description>The study include 8-week antihyperglycemic agent ( AHA ) wash-off period* ( include 2-week single-blind placebo run-in period ) follow 24-week double-blind treatment period . All participant receive open-label acarbose minimum dose 50 mg three time daily ( t.i.d . ) run-in treatment period . * : Wash-off applicable patient acarbose another AHA .</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Acarbose</mesh_term>
	<mesh_term>Sitagliptin Phosphate</mesh_term>
	<mesh_term>Glimepiride</mesh_term>
	<criteria>T2DM acarbose alone stable dose least 50 mg t.i.d . ( three time day ) least 10 week acarbose stable dose least 50 mg t.i.d . ( three time day ) least 10 week combination another antihyperglycemic agent ( AHA ) least 18 year age ( participant India : 18 65 year age ) male female unlikely conceive ( reproductive potential , agree remain abstinent use [ partner use ] acceptable birth control reproductive potential ) history type 1 diabetes mellitus use thiazolidinedione ( TZD ) , dipeptidyl peptidase4 ( DPP4 ) inhibitor , glucagonlike peptide1 ( GLP1 ) receptor agonist , insulin follow cardiovascular disorder : acute coronary syndrome ; new worsening symptom coronary heart disease ; coronary artery intervention ; stroke transient ischemic neurological disorder liver kidney disease cancer clinically significant disease disorder judge Investigator</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2015</verification_date>
	<keyword>Type 2 diabetes mellitus</keyword>
	<keyword>T2DM</keyword>
</DOC>